SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Files An 8-K Other Events
Item 8.01. Other Events.
On April 19, 2017, Sorrento Therapeutics, Inc. (the Company)
issued a press release announcing the closing of its previously
announced underwritten public offering of shares of its common
stock. In the offering, the Company sold an aggregate of
23,625,084 shares of its common stock at a public offering price
of $2.00 per share. A copy of the press release is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description | |
| 99.1 | Press Release, dated April 19, 2017. |
About SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE)
Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy. SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Recent Trading Information
SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) closed its last trading session up +0.05 at 1.65 with 3,442,305 shares trading hands.
